KRMDHealthcare · Medical Instruments & SuppliesThe 4 Wall Street analysts covering KORU Medical Systems, Inc. hold a median 12-month price target of $6 — +83.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores KORU Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (90): The business earns solid, repeatable profits on what it owns.
Momentum (45): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KRMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +83.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Mar 2026 | B. Riley Securities | Maintains | Buy | $7.00 → $8.00 |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | $6.00 |
| 22 Dec 2025 | Lake Street | Maintains | Buy | — |
| 17 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 7 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 8 May 2025 | Piper Sandler | Maintains | Neutral | — |
| 14 Feb 2025 | Piper Sandler | Downgrade | Neutral | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | Lake Street | Maintains | Buy | — |
| 14 Nov 2024 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 14 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 8 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 14 Mar 2024 | B. Riley Securities | Reiterates | Buy | — |
| 7 Dec 2023 | Canaccord Genuity | Reiterates | Buy | — |
| 7 Sept 2023 | B. Riley Securities | Initiates | Buy | — |
| 7 Sept 2023 | Lake Street | Initiates | Buy | — |
| 3 Aug 2023 | Piper Sandler | Maintains | Overweight | — |
| 6 Jan 2023 | Piper Sandler | Maintains | Overweight | — |
| 10 Nov 2022 | Canaccord Genuity | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KRMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, KORU Medical Systems, Inc. returned −15.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 38% of US stocks
Cheaper than 11% of US stocks
Cheaper than 97% of US stocks
Higher than 67% of US stocks
Higher than 58% of US stocks
Higher than 78% of US stocks
Higher than 55% of US stocks
Higher than 25% of US stocks
Higher than 36% of US stocks
Higher than 34% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
KORU Medical Systems, Inc. has a market value of $143.1M and an enterprise value of $135.8M.
Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter grew 18.2% year on year.
Net income over the same four quarters: −$1.8M, a −4.0% net margin.
Free cash flow in the twelve months to 30 June 2026: $243K.
Trailing P/E: −51.9×; forward P/E: 88.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
KORU Medical Systems, Inc. employs 73 people — $618K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own KORU Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
KORU Medical Systems announced it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. Management is scheduled to present in November.
Why it matters — The announcement gives KRMD watchers information about an upcoming investor-conference appearance by management.
KORU Medical Systems announced it will report third-quarter 2026 financial results on November 10, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that day.
Why it matters — KRMD watchers can note the scheduled date and time for the company’s results and management discussion.
Seeking Alpha published a transcript of KORU Medical Systems, Inc.'s Q2 2026 earnings call. The transcript covers the company's quarterly earnings discussion for the second quarter of fiscal year 2026.
Why it matters — A KRMD watcher would care because the earnings call transcript provides detailed commentary from management on the company's latest quarterly results, which is a key source for assessing recent performance.
KORU Medical Systems reported second-quarter revenue of $12 million, up 18% year over year, supported by domestic patient starts, market-share gains, and international demand. The company posted its first positive net income since 2019, raised its full-year gross-margin outlook, and narrowed revenue guidance because certain international prefilled-syringe market launches are taking longer than expected.
Why it matters — For KRMD watchers, the quarter marks a profitability milestone and improved margin outlook while also signalling a more cautious revenue forecast tied to slower international launch timing.
KORU Medical Systems reported Q2 earnings of $0.01 per share, beating the Zacks Consensus Estimate of a $0.02 per share loss. This compares with break-even earnings per share in the same quarter a year ago.
Why it matters — The earnings beat over consensus estimates marks a favorable quarterly result for KRMD watchers, as the company turned a profit relative to the expected loss.
The 4 Wall Street analysts covering KORU Medical Systems, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering KORU Medical Systems, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks KORU Medical Systems, Inc. 94 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, KORU Medical Systems, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +83.5% from the last close, and Ticker Nerd's factor model ranks KORU Medical Systems, Inc. 94 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering KORU Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
KORU Medical Systems, Inc. returned -15.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
KORU Medical Systems Inc. is a medical technology company that develops, manufactures, and commercializes subcutaneous infusion solutions for patients who require ongoing drug delivery.
The most recent item we track (Business Wire, 4 Nov 2026): "KORU Medical Systems to Participate in Upcoming Investor Conferences". KORU Medical Systems announced it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. Management is scheduled to present in November.
KORU Medical Systems Inc. is a medical technology company that develops, manufactures, and commercializes subcutaneous infusion solutions for patients who require ongoing drug delivery. KORU Medical Systems Inc. focuses on home and specialty infusion care, with products designed to support the administration of therapies for chronic and complex conditions. Its portfolio includes the FREEDOM infusion systems, syringe drivers, subcutaneous safety needle sets, and precision flow rate tubing, which work together as integrated mechanical delivery solutions. The company serves healthcare providers, patients, and pharmaceutical partners in the United States and international markets, with applications across home care, emergency care, hospital settings, nursing homes, and other medical facilities. KORU Medical Systems Inc. plays a specialized role in the medical devices market by helping make subcutaneous infusion therapies more practical, patient-centric, and widely usable across different care environments.
CEO Mr. Adam Kalbermatten · 73 employees · United States · https://www.korumedical.com
